Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2022

View Archived Issues

Blocking UBE2N evades oncogenic immune signaling in AML

TYK2 inhibitors described by Ennovabio (Zhejiang) Pharmaceuticals, Shanghai Ennova Biopharmaceutical

New Bruton tyrosine kinase inhibitors identified at Beijing Innocare Medical Technology

Chengdu Fanxi Biopharma discovers thyroid hormone receptor alpha/beta agonists

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent Nav1.8 channel blockers

Medshine Discovery identifies new cyclin/CDK inhibitors

RIG1 activation confers protection against SARS-CoV-2 infection in mice

Study reveals dopamine as a sleep disorders target

Targeting PTP1B enhances T cell-mediated antitumor immunity

FDA grants orphan drug designation to HT-KIT for mastocytosis

Discovery of novel MDM2 inhibitor with antitumor activity in p53 wild-type cancer models

Del-1 potentiates BCI efficacy by blockade of tumor-infiltrating neutrophils

Bright Minds' BMB-101 for Dravet syndrome completes 28-day repeat toxicity studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...